bioAffinity Technologies, Inc. (BIAF) Price & Analysis

Compare

111 Followers

BIAF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.16 - $2.26

Previous CloseN/A

Volume17.91K

Average Volume (3M)456.50K

Market Cap

$6.80M

Enterprise Value$6.77M

Total Cash (Recent Filing)$444.71K

Total Debt (Recent Filing)$1.33M

Price to Earnings (P/E)―

Beta-2.29

Next Earnings

Nov 12, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding28,468,613

10 Day Avg. Volume262,145

30 Day Avg. Volume456,503

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.99

Enterprise Value/Revenue0.77

Enterprise Value/Gross Profit2.23

Enterprise Value/Ebitda-0.75

Forecast

1Y Price Target

$0.50

Price Target Upside108.33% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Market ExpansionThe initial success of CyPath Lung in Texas has expanded to several other states through referrals and word-of-mouth, with expected momentum to continue through 2025.

Product AdoptionThe number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.

Sales GrowthCyPath Lung sales were up 276% year-over-year, indicating strong growth potential despite some temporary setbacks.

Bears Say

Capital ConstraintsThe company's capital constraints remain a concern, impacting the ability to operate profitably without raising additional funds.

Financial PerformanceAnalysts are lowering their 2025 and 2026 revenue estimates, and widening their 2025 and 2026 GAAP loss per share estimates.

Shareholder ImpactThe company needs to raise additional capital immediately, which could lead to share dilution for current shareholders.

bioAffinity Technologies, Inc. News

BioAffinity Technologies files to sell 12.61M shares of common stock for holders

16:17 EDT BioAffinity Technologies (BIAF) files to sell 12.61M shares of common stock for holders Published first on...

10d ago

BIAF

BioAffinity Technologies announces surge in CyPath Lung sales

BioAffinity Technologies (BIAF) announced a significant surge in commercial sales of its CyPath Lung. The company said following...

26d ago

BIAF

bioAffinity Technologies Prepares for H.C. Wainwright Conference

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an update. bioAffinity Technologies, Inc., a Delaware corporation, has prepared...

3d ago

BIAF

bioAffinity Technologies’ CyPath® Lung Test Featured in U.S. Medicine

The latest update is out from bioAffinity Technologies, Inc. ( ($BIAF) ). On September 3, 2025, bioAffinity Technologies...

5d ago

BIAF

bioAffinity Amends Warrant Floor Price in Recent Agreement

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an update. On September 2, 2025, bioAffinity Technologies, Inc. announced...

6d ago

BIAF

Hold Rating for bioAffinity Technologies Amid Growth Prospects and Financial Challenges

Maxim Group analyst Anthony Vendetti has maintained their neutral stance on BIAF stock, giving a Hold rating on...

17d ago

BIAF

bioAffinity Technologies Appoints New Board Members

bioAffinity Technologies, Inc. ( ($BIAF) ) has provided an announcement. On August 12, 2025, bioAffinity Technologies appointed Roberto...

21d ago

BIAF

bioAffinity Technologies Reports Strong Growth in Lung Test Sales

bioAffinity Technologies, Inc. ( ($BIAF) ) has released its Q2 earnings. Here is a breakdown of the information...

25d ago

BIAF

bioAffinity Technologies Secures $1.2M Through Private Placement

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an announcement. On August 13, 2025, bioAffinity Technologies, Inc. entered...

25d ago

BIAF

bioAffinity Technologies Sees Surge in CyPath® Lung Test Sales

bioAffinity Technologies, Inc. ( ($BIAF) ) has issued an update. On August 13, 2025, bioAffinity Technologies announced a...

26d ago

BIAF

bioAffinity’s CyPath® Lung Test Detects Early Cancer

bioAffinity Technologies, Inc. ( ($BIAF) ) has issued an update. On July 29, 2025, bioAffinity Technologies announced a...

1M ago

BIAF

bioAffinity Technologies Approves Key Proposals at Annual Meeting

bioAffinity Technologies, Inc. ( ($BIAF) ) has shared an announcement. At the 2025 Annual Meeting of Stockholders held...

2M ago

BIAF

BioAffinity Technologies awarded new Canadian patent for CyPath Lung

BioAffinity Technologies (BIAF) announced its patent related to a method to detect lung disease through flow cytometry analysis...

2M ago

BIAF

BioAffinity receives China patent for noninvasive lung cancer diagnostic

BioAffinity Technologies (BIAF) announced it has received notification of allowance from the China National Intellectual Property Administration for...

2M ago

BIAF

BIAF FAQ

What was bioAffinity Technologies, Inc.’s price range in the past 12 months?

bioAffinity Technologies, Inc. lowest stock price was $0.16 and its highest was $2.26 in the past 12 months.

What is bioAffinity Technologies, Inc.’s market cap?

bioAffinity Technologies, Inc.’s market cap is $6.80M.

When is bioAffinity Technologies, Inc.’s upcoming earnings report date?

bioAffinity Technologies, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 65 days.

How were bioAffinity Technologies, Inc.’s earnings last quarter?

bioAffinity Technologies, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$0.07.

Is bioAffinity Technologies, Inc. overvalued?

According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does bioAffinity Technologies, Inc. pay dividends?

bioAffinity Technologies, Inc. does not currently pay dividends.

What is bioAffinity Technologies, Inc.’s EPS estimate?

bioAffinity Technologies, Inc.’s EPS estimate is -0.09.

How many shares outstanding does bioAffinity Technologies, Inc. have?

bioAffinity Technologies, Inc. has 28,468,613 shares outstanding.

What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?

bioAffinity Technologies, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went down -7.143%.

Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?

Currently, no hedge funds are holding shares in BIAF

Company Description

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (BIAF) is a biotechnology company focused on developing non-invasive diagnostic tests and targeted therapies to detect and treat early-stage cancer. The company operates within the healthcare and biotechnology sectors, leveraging its expertise in cellular biology to create innovative solutions that address unmet medical needs. Its core products include diagnostic assays and therapeutic agents designed to improve patient outcomes by enabling early detection and treatment of cancer.

bioAffinity Technologies, Inc. (BIAF) Earnings & Revenues

Historic Earnings Reports

BIAF Stock 12 Month Forecast

Average Price Target

$0.50

▲(108.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.24,0.26,0.27999999999999997,0.3,0.32,0.33999999999999997,0.36,0.38,0.4,0.42,0.44,0.45999999999999996,0.48,{"y":0.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.24,0.26,0.27999999999999997,0.3,0.32,0.33999999999999997,0.36,0.38,0.4,0.42,0.44,0.45999999999999996,0.48,{"y":0.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.24,0.26,0.27999999999999997,0.3,0.32,0.33999999999999997,0.36,0.38,0.4,0.42,0.44,0.45999999999999996,0.48,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.45,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.4,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.48,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.24,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >